Heart failure & cardiomyopathiesRandomised controlled trial
Impact of Vasodilators on Diuretic Response in Patients with Congestive Heart Failure: A Mechanistic Trial of Cimlanod (BMS-986231)
- Randomised controlled trial
- double-blind
- crossover
- mechanistic
Authors' conclusion
For patients with heart failure and congestion, vasodilatation with agents such as cimlanod reduces the response to diuretic agents, which may offset any benefit from acute reductions in cardiac preload and afterload.
Study context
- Population
- Patients with LVEF <45%, increased NT-proBNP, receiving loop diureticscrossover
- Participants
- 21 patients
- Comparison
- Cimlanod vs placebo infusion before intravenous (IV) furosemide
- Primary endpoint
- Urine volume after a 40 mg IV furosemide bolus given 4 h after infusion start
- Follow-up
- 4 h after the furosemide bolus
Primary result
As reported in the abstract
Urine volume · 4 h post-furosemide
P = 0.002
Further findings
Sodium excretion, SBP, eGFR, haemoglobin · 4 h post-furosemide
- Total sodium excretion lower with cimlanod
- P = 0.004
- Fractional sodium excretion lower with cimlanod
- P = 0.016
- SBP lower with cimlanod
- P < 0.001
- eGFR lower with cimlanod
- P = 0.012
- Haemoglobin (index of plasma volume expansion) lower with cimlanod
- P = 0.010
Haemodynamics during cimlanod infusion
- Cimlanod increased cardiac output and reduced BP without affecting cardiac power index
Original publication
Impact of Vasodilators on Diuretic Response in Patients with Congestive Heart Failure: A Mechanistic Trial of Cimlanod (BMS-986231). Eur J Heart Fail. Published 28 December 2023. doi:10.1002/ejhf.3077
Summarised from the published abstract; every number is checked against it